1. RODNA
  2. CONICET
  3. CONICET
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.provenanceCONICET-
dc.creatorAustin, Matthew-
dc.creatorYang, Yu Ching-
dc.creatorVittinghoff, Eric-
dc.creatorAdami, Silvano-
dc.creatorBoonen, Steven-
dc.creatorBauer, Douglas C-
dc.creatorBianchi, Gerolamo-
dc.creatorBolognese, Michael A.-
dc.creatorChristiansen, Claus Bohn-
dc.creatorEastell, Richard-
dc.creatorGrauer, Andreas-
dc.creatorHawkins, Federico-
dc.creatorKendler, David L.-
dc.creatorOliveri, María Beatriz-
dc.creatorMcClung, Michael R.-
dc.creatorReid, Ian R.-
dc.creatorSiris, Ethel S.-
dc.creatorZanchetta, Jose-
dc.creatorZerbini, Cristiano A.F.-
dc.creatorLibanati, Cesar-
dc.creatorCummings, Steven R.-
dc.date2019-01-04T18:38:20Z-
dc.date2019-01-04T18:38:20Z-
dc.date2012-03-
dc.date2019-01-02T19:40:11Z-
dc.date.accessioned2019-04-29T15:30:00Z-
dc.date.available2019-04-29T15:30:00Z-
dc.date.issued2019-01-04T18:38:20Z-
dc.date.issued2019-01-04T18:38:20Z-
dc.date.issued2012-03-
dc.date.issued2019-01-02T19:40:11Z-
dc.identifierAustin, Matthew; Yang, Yu Ching; Vittinghoff, Eric; Adami, Silvano; Boonen, Steven; et al.; Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures; American Society for Bone and Mineral Research; Journal of Bone and Mineral Research; 27; 3; 3-2012; 687-693-
dc.identifier0884-0431-
dc.identifierhttp://hdl.handle.net/11336/67431-
dc.identifierCONICET Digital-
dc.identifierCONICET-
dc.identifier.urihttp://rodna.bn.gov.ar:8080/jspui/handle/bnmm/295246-
dc.descriptionDual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However, previous patient-level studies suggest that BMD changes explain little of the fracture risk reduction observed with osteoporosis treatment. We investigated the relevance of DXA BMD changes as a predictor for fracture risk reduction using data from the FREEDOM trial, which randomly assigned placebo or denosumab 60 mg every 6 months to 7808 women aged 60 to 90 years with a spine or total hip BMD T-score < -2.5 and not < -4.0. We took a standard approach to estimate the percent of treatment effect explained using percent changes in BMD at a single visit (months 12, 24, or 36). We also applied a novel approach using estimated percent changes in BMD from baseline at the time of fracture occurrence (time-dependent models). Denosumab significantly increased total hip BMD by 3.2%, 4.4%, and 5.0% at 12, 24, and 36 months, respectively. Denosumab decreased the risk of new vertebral fractures by 68% (p < 0.0001) and nonvertebral fracture by 20% (p = 0.01) over 36 months. Regardless of the method used, the change in total hip BMD explained a considerable proportion of the effect of denosumab in reducing new or worsening vertebral fracture risk (35% [95% confidence interval (CI): 20%-61%] and 51% [95% CI: 39%-66%] accounted for by percent change at month 36 and change in time-dependent BMD, respectively) and explained a considerable amount of the reduction in nonvertebral fracture risk (87% [95% CI: 35% - >100%] and 72% [95% CI: 24% - >100%], respectively). Previous patient-level studies may have underestimated the strength of the relationship between BMD change and the effect of treatment on fracture risk or this relationship may be unique to denosumab. Copyright © 2012 American Society for Bone and Mineral Research.-
dc.descriptionFil: Austin, Matthew. Amgen Incorporated; Estados Unidos-
dc.descriptionFil: Yang, Yu Ching. Amgen Incorporated; Estados Unidos-
dc.descriptionFil: Vittinghoff, Eric. University of California; Estados Unidos-
dc.descriptionFil: Adami, Silvano. Universita di Verona; Italia-
dc.descriptionFil: Boonen, Steven. Katholikie Universiteit Leuven; Bélgica-
dc.descriptionFil: Bauer, Douglas C. University of California; Estados Unidos-
dc.descriptionFil: Bianchi, Gerolamo. Azienda Sanitaria Genovese; Italia-
dc.descriptionFil: Bolognese, Michael A.. Bethesda Health Research Center; Estados Unidos-
dc.descriptionFil: Christiansen, Claus Bohn. Center For Clinical And Basic Research As; Estados Unidos-
dc.descriptionFil: Eastell, Richard. University Of Sheffield; Reino Unido-
dc.descriptionFil: Grauer, Andreas. Amgen Incorporated; Estados Unidos-
dc.descriptionFil: Hawkins, Federico. Hospital Universitario 12 de Octubre; España-
dc.descriptionFil: Kendler, David L.. University of British Columbia; Canadá-
dc.descriptionFil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina-
dc.descriptionFil: McClung, Michael R.. Oregon Osteoporosis Center; Estados Unidos-
dc.descriptionFil: Reid, Ian R.. The University of Auckland; Nueva Zelanda-
dc.descriptionFil: Siris, Ethel S.. Columbia University; Estados Unidos-
dc.descriptionFil: Zanchetta, Jose. Universidad del Salvador; Argentina-
dc.descriptionFil: Zerbini, Cristiano A.F.. Centro Paulista de Investigação Clinica; Brasil-
dc.descriptionFil: Libanati, Cesar. Amgen Incorporated; Estados Unidos-
dc.descriptionFil: Cummings, Steven R.. University of California; Estados Unidos-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.languageeng-
dc.publisherAmerican Society for Bone and Mineral Research-
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1002/jbmr.1472-
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.1472-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/-
dc.sourcereponame:CONICET Digital (CONICET)-
dc.sourceinstname:Consejo Nacional de Investigaciones Científicas y Técnicas-
dc.sourceinstacron:CONICET-
dc.source.urihttp://hdl.handle.net/11336/45474-
dc.subjectBONE MINERAL DENSITY-
dc.subjectDENOSUMAB-
dc.subjectFRACTURE-
dc.subjectPERCENT OF TREATMENT EFFECT EXPLAINED-
dc.subjectSURROGATE-
dc.subjectMedicina Critica y de Emergencia-
dc.subjectMedicina Clínica-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.titleRelationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.typeinfo:ar-repo/semantics/articulo-
Aparece en las colecciones: CONICET

Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro sencillo del ítem